论文部分内容阅读
目的探讨重组人组织型纤溶酶原激活物(rt-PA)静脉溶栓联合依达拉奉注射液(必存)治疗急性脑梗死患者的临床疗效。方法 98例急性脑梗死患者,采用随机数字表法对照组和观察组,各49例。对照组患者采用单一rt-PA静脉溶栓治疗,观察组患者采用rt-PA静脉溶栓联合必存治疗。对比两组临床疗效。结果观察组患者治疗后神经功能缺损评分(NIHSS)及日常生活能力评分(BI)分别为(3.24±0.21)、(89.43±7.86)分;对照组分别为(8.75±1.65)、(71.23±6.46)分。治疗后两组NIHSS及BI评分对比差异具有统计学意义(P<0.05)。结论 rt-PA静脉溶栓联合必存治疗急性脑梗死患者具有显著的临床疗效,可有效改善患者的神经缺损症状,提高患者的日常生活能力,值得推广及采纳。
Objective To investigate the clinical efficacy of recombinant human tissue plasminogen activator (rt-PA) intravenous thrombolysis combined with edaravone injection (required) in patients with acute cerebral infarction. Methods A total of 98 patients with acute cerebral infarction were randomly divided into control group and observation group with 49 cases in each group. Patients in the control group received single rt-PA intravenous thrombolysis and patients in the observation group received rt-PA intravenous thrombolysis in combination with essential drugs. Compare two groups clinical curative effect. Results The scores of NIHSS and BI in the observation group were (3.24 ± 0.21) and (89.43 ± 7.86) points after treatment respectively, while those in the control group were (8.75 ± 1.65) and (71.23 ± 6.46 )Minute. There was significant difference between NIHSS and BI scores in the two groups after treatment (P <0.05). Conclusion rt-PA combined with intravenous thrombolytic therapy in patients with acute cerebral infarction has significant clinical efficacy, which can effectively improve the symptoms of patients with neurological deficits and improve the daily living ability of patients, which is worth promoting and adopting.